INTRODUCTION
H EPATOCELLULAR CARCINOMA (HCC) is a major cause of mortality in patients with cirrhosis all over the world. Treatment options, such as resection, local ablation, transcatheter arterial chemoembolization (TACE), and liver transplantation have been carried out in patients with HCC. [1] [2] [3] [4] [5] [6] [7] Sorafenib has also been established as the standard treatment for advanced HCC, but the survival rate and safety remain unsatisfactory. 8, 9 Transcatheter arterial chemoembolization has been recognized as a treatment option for patients with intermediate HCC and has been shown to improve survival. [2] [3] [4] In this procedure, various anticancer agents, tools, and techniques for TACE have been constantly developed. In Japan, several anticancer agents, such as epirubicin, doxorubicin, mitomycin-c, carboplatin, and cisplatin are commonly used. Unfortunately, we have not been able to stably use these agents in suspension or emulsion in Lipiodol (Terumo, Tokyo, Japan) because they are hydrophilic and, therefore, water soluble.
Recently, we were able to use a novel lipophilic cisplatin derivative that can be suspended in Lipiodol, an oily lymphographic agent: miriplatin ([SP-4-2]-[(1R, 2R)-cyclohexane-1, 2-diamine-N, N]-bis [tetradecanoate-O] platinum monohydrate) (Dainippon Sumitomo Pharmaceutical Co., Ltd., Osaka, Japan). [10] [11] [12] [13] Because miriplatin has an ideal pharmacological structure in the treatment of HCC with Lipiodol using TACE, there are several reports of the usefulness of miriplatin in this procedure. [14] [15] [16] However, Iwazawa et al. 17 reported in their retrospective study that the local control effects of TACE for HCC using miriplatin is significantly less than those using epirubicin. Furthermore, Aramaki et al. 15 and Handa et al. 16 could not show a significant difference of local control between miriplatin-TACE and epirubicin-TACE. However, to our knowledge, there is no prospective randomized controlled trial that compares the local control effects of TACE for HCC with miriplatin or epirubicin. Therefore, the aim of the present, randomized, controlled study was to compare the local control efficacy of TACE for HCC with miriplatin against that with epirubicin.
METHODS
Study design and patient selection T HIS OPEN-LABEL, RANDOMIZED, controlled trial was carried out at Kitasato University East Hospital (Sagamihara, Japan) between July 2010 and June 2014. The trial was undertaken with the approval of the Kitasato University Ethics Committee and in accordance with the Declaration of Helsinki (1989) of the World Medical Association. Written informed consent was obtained from each patient.
The study group consisted of patients with HCC who could not undergo a resection or local ablation at the Kitasato University East Hospital from July 2010 through June 2013. The eligibility criteria also included: (i) patients with HCC that were histologically or clinically confirmed and were unsuitable for resection or locoregional therapy; (ii) tumor-node-metastasis stage 2 or 3; (iii) HCC showing arterial phase enhancement; (iv) Child-Pugh liver function class A or B; (v) no history of treatment for HCC within the previous 3 months; (vi) a life expectancy of 3 months or longer; (vii) an Eastern Cooperative Oncology Group performance status score of ≤2; (viii) hematologic function (white blood cell count, ≥2 × 10 3 ; platelet count, ≥50 × 10 3 ; hemoglobin, ≥8.0 g/dL; and prothrombin time, ≥40%); (ix) hepatic function (albumin, ≥2.8 g/ dL; and total bilirubin, ≤2 mg/dL); and (x) renal function (serum creatinine, upper limit of normal range). The exclusion criteria also included: (i) vascular invasion or bile duct invasion; (ii) extrahepatic metastasis; (iii) major arterioportal shunt in the liver; (iv) combination with locoregional therapy; (v) hepatic encephalopathy or refractory ascites; (vi) adjuvant therapy with interferon, vitamin A, or anticancer agents; (vii) medical history of hypersensitivity of iodine or contrast media; (viii) severe thyroid disease; (ix) pregnant, lactating, or suspected to be pregnant; and (x) deemed inappropriate to participate in this study by their physicians.
Drug preparation
The miriplatin-iodized oil suspension was prepared by dissolving 70 mg miriplatin into 3.5 ml of iodized oil (Lipiodol Ultrafluid; Terumo), while the epirubiciniodized oil emulsion was prepared by dissolving 10 mg epirubicin into 1 mL iopamidol (Iopamiron 370; Bayer Schering Pharma, Osaka, Japan) and then mixing that into 2 mL iodized oil.
Treatment
All patients were treated by the Seldinger method, for which a catheter was introduced into their right femoral artery. Following that procedure, they underwent angiography of the celiac and super mesenteric arteries. Prior to TACE, ultraselective, subsegmental, and segmental microcatheterization was carried out to confirm whether or not the target tumor was actually located within the treatment area.
Before the injection, we warmed the syringe with the miriplatin-iodized oil suspension to at least 60°C in a sterile state. The miriplatin-iodized oil suspension or the epirubicin-iodized oil emulsion was then injected as soon as possible. After we confirmed the stagnation of the Lipiodol suspension or emulsion in the target lesion, we slowly injected gelatin sponge particles (Gelpart; Nippon Kayaku, Tokyo, Japan) of 1-mm diameter to embolize the feeding arteries.
Evaluation of treatment response
Image evaluation of the tumor was undertaken within 28 days before the initial TACE. After the start of treatment with the study drug, it was carried out 42 days after the initial (subsequent) TACE, and every 56 days thereafter. Computed tomography images were obtained after an injection of 120 mL iodine contrast (300 mg/mL) with an average flow rate of 3.0 mL/s by using an automatic power injector. Arterial phase imaging was carried out 15-19 s after achievement of 100 Hounsfield units attenuation of the descending aorta, measured using a bolus tracking method. A delay of 30-33 s after the arterial phase was obtained for the portal venous phase acquisition. The delay time was 180 s for the equilibrium phase imaging following administration of a contrast medium.
TACE with miriplatin in
Slice collimation was 5 mm in the arterial and portal phases and 8 mm in the other two phases at a pitch of 1.5 mm. Tumor response was evaluated separately according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) 18 in a non-blinded fashion by both the hepatologist and the radiologist, who both specialized in liver cancer. The target lesions were defined by both evaluators for all patients on their pretreatment computed tomography scans. Then each physician made separate measurements and determined the tumor response. In case of disagreement, a consensus was reached. A target lesion was defined as the contrast enhanced portion of the lesion at the arterial phase for the mRECIST assessment. According to the mRECIST: complete response (CR) was defined as the absence of arterially enhanced areas in all target lesions, partial response (PR) was at least a 30% decrease in the sum of diameters of viable target lesions (enhancement in the arterial phase), taking the baseline sum of the diameters of target lesions as references, and progressive disease (PD) was an increase of at least 20% in the sum of the diameters of viable target lesions, taking the smallest sum of the diameters of viable target lesions (enhanced) recorded from when the treatment started as references. Stable disease (SD) was defined as any cases that do not qualify for either PR or PD. We also recorded the best variation (maximal decrease or minimal increase) in the sum of the largest lesion's dimensions for each patient. 18 All measurable lesions, up to a maximum of two lesions per liver, were identified as target lesions and recorded and measured at baseline based on RECIST 1.1.
19 RECIST 1.1 reduced the number of lesions to select as target lesions to a maximum of two lesions per organ (the liver in the present study) and five lesions in total. Analyses on a large prospective database has shown that assessment of five versus 10 lesions per patient did not affect the overall response rate, and that progression-free survival was only minimally affected. 20 
End-points
The primary end-point of the study was time to tumor progression (TTP). The TTP was defined as the time from randomization to PD (according to mRECIST) on the basis of independent radiological review. 18 Therefore, we had been observing the patients until the tumor response was defined as PD. Secondary end-points included tumor response and safety.
Assessment
Examination of vital signs, body weight, Eastern Cooperative Oncology Group performance status, Child-Pugh score, clinical chemistry tests, and hematology tests were carried out at the time of screening, 14, 28, and 42 days after the initial (subsequent) TACE, and every 28 days thereafter. A safety follow-up test was undertaken 30 days after the last administration of the study drug. Concerning safety, all adverse events and adverse drug reactions that occurred between the day of the start of treatment with the study drug and the day of completion of observation in the clinical trial period were counted. All adverse events were recorded on the electronic case report form using the Common Terminology Criteria for Adverse Events terminology, version 4.02.
Intention-to-treat analyses
Data were designed to be primarily analyzed using an intention-to-treat model supplemented with per-protocol analysis. Patients were followed up until they reached the end-points or were lost to follow-up.
Statistical analyses
For a comparison of categorical variables, the χ 2 -test or Fisher's exact test were used. The Mann-Whitney nonparametric U-test was used for the unpaired data, and the Wilcoxon rank sum test was used for the paired data. The impact of the clinical variables on tumor response was estimated by calculating the risk ratios (RRs) and the 95% confidence intervals (95% CIs). Cumulative probability of TTP was estimated using the Kaplan-Meier method, and differences were assessed by the log-rank test. Factors affecting TTP were first subjected to univariate analysis with the log-rank test. Variables that achieved statistical significance (P < 0.05) or marginal significance (P < 0.10) on univariate analysis were entered into a multivariate Cox proportion hazard model to identify significant independent factors. Statistical analyses were carried out with the statistical package, SPSS Base 17.0 J for Windows (SPSS, Chicago, IL, USA). All P-values were two-tailed. All differences with a P-value of less than 0.05 were considered significant.
RESULTS

Patients and baseline characteristics
T WO HUNDRED JAPANESE patients were enrolled in this study. Two patients could not undergo TACE because 1 patient's (1%) condition worsened before the treatment and 1 patient (1%) had allergic reactions to the contrast medium. We analyzed 198 patients (99 patients each in the miriplatin arm and the epirubicin arm) who underwent TACE (Fig. 1 ). There were 137 events: 61 and 76 events for miriplatin and epirubicin,
respectively. There were 61 censored cases: 38 events for miriplatin (16 patients, no events; 10 patients, lost to follow-up; and 22 patients, treatment for new lesions); and 23 patients for epirubicin (3 patients, no events; 2 patients, lost to follow-up; and 18 patients, treatment for new lesions). The median dose was 30 mg (range, 6-120 mg) and 14 mg (range, 2-54 mg) for miriplatin and epirubicin, respectively, and there was a significant difference in iodized oil doses (1.5 mL vs. 3.2 mL, respectively: P = 0.001) between the two groups. However, there were no significant differences in the characteristics except the iodized oil doses between the two groups including the tumor categories in Table 1 .
Primary end-point
The median TTP of all the patients was 7.2 months (95% CI, 6.4-7.9). The median TTP in the epirubicin group was 5.9 months (95% CI, 4.8-7.0), whereas the median TTP in miriplatin was 7.6 months (95% CI, 5.8-9.4) (Fig. 2 ). There was a significant difference between the two groups (P = 0.021; RR, 1.488; 95% CI, 1.061-2.086).
Secondary end-points
According to m-RECIST, in the miriplatin group, 38 patients (38%) had CR, 41 patients (41%) had PR, 2 patients (2%) had SD, and 18 patients (18%) had PD. In the epirubicin group, 53 patients (53%) had CR, 24 patients (24%) had PR, 12 patients (12%) had SD, and 10 patients (10%) had PD ( Table 2 ). There was no significant difference in the response rate: 79.8% (95% CI, 71.9-87.7%) in the miriplatin group and 77.8% (95% CI, 69.6-88.6%) in the epirubicin group (P = 0.862) ( Table 3 ). We did not include survival in the present study because more than 50% of the patients survived to the end of the analysis.
Safety
Adverse events and adverse drug reactions observed in the miriplatin and epirubicin arms are shown in Table 4 . The events that occurred with almost the same incidence in the miriplatin arm and the epirubicin arm were as follows (miriplatin arm vs. epirubicin arm, respectively): fever (27% vs. 30%), abdominal pain (25% vs. 34%), anorexia (15% vs. 20%), nausea (12% vs. 13%), diarrhea (2% vs. 3%), ascites (2% vs. 5%), leukocytosis (34% vs. 39%), anemia (55% vs. 52%), thrombocytopenia (95% vs. 90%), albumin decrease (94% vs. 94%), blood bilirubin increase (60% vs. 58%), and aspartate aminotransferase increase (95% vs. 97%). The proportions of patients who experienced serious adverse events were 37% in the miriplatin arm and 46% in the epirubicin arm. No study drug-related deaths occurred (Table 4 ). 
Univariate and multivariate analysis of factors affecting tumor progression
The results of the univariate analysis revealed that α-fetoprotein (AFP) levels (P = 0.018), des-γ-carboxyprothrombin (DCP) levels (P = 0.01), methods of TACE Figure 2 Kaplan-Meier curve for time to progression in patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization with miriplatin or epirubicin. There was a significant difference between the miriplatin and epirubicin groups by the log-rank test (P = 0.021; risk ratio, 1.488; 95% confidence interval, 1.061-2.086). (segmental or ultraselective/subsegmental) (P = 0.003), and the anticancer agent (miriplatin or epirubicin) (P = 0.021) were the tumor progressive factors that significantly affected local tumor control. Furthermore, multivariate analysis revealed that the independent factors affecting local tumor control were AFP levels (RR, 1.574; 95% CI, 1.118-2.216; P = 0.009), DCP levels (RR, 1.540; 95% CI, 1.085-2.184; P = 0.016), TACE method (segmental or ultraselective/subsegmental) (RR, 1.715; 95% CI, 1.197-2.457; P = 0.003) and the anticancer agent (miriplatin or epirubicin) (RR, 1.636; 95% CI, 1.161-2.306; P = 0.005) ( Table 5 ).
DISCUSSION
T O OUR KNOWLEDGE, this is the first prospective, randomized, controlled trial to compare the local control efficacy of TACE for HCC with miriplatin or with epirubicin. We showed a significant difference in the TTP between the two groups, although the adverse events and adverse drug reactions did not differ significantly between them. Therefore, we would like to suggest the usefulness of miriplatin in this procedure for unresectable HCCs.
The prospective study design and rigid evaluation are strengths in the present study. Prior to this study, there were three retrospective studies that compared the local control efficacy of TACE for HCC with miriplatin or epirubicin. [15] [16] [17] In those studies, one study showed that the local control effects of TACE for HCC using miriplatin was significantly less than those using epirubicin. 17 However, in their study, there was no standard evaluation method for the local tumor progression whereas, in the present study, we evaluated the target lesion by mRECIST (the definition of maximum number of target nodules based on RECIST 1.1). In addition, they evaluated tumor effect dependent on the previous imaging findings and laboratory data. We showed that the TACE method (segmental or ultraselective/subsegmental) and tumor markers (AFP and DCP) are very important predictive factors for HCC progression after TACE with miriplatin or with epirubicin. Therefore, it is important that we evaluated the target tumor response separately without any patient information by both the hepatologist and the radiologist.
However, we could not explain the significant efficacy of miriplatin only by the present study's design and strict evaluation. We speculated that this efficacy was a result of using warmed miriplatin-iodized oil suspension. The usefulness of warmed miriplatin-iodized oil suspension was first reported in 2013 by Seko et al. 21 Generally, one of the most significant physicochemical properties of miriplatin suspension is its high viscosity. Therefore, it cannot sufficiently flow into small feeding arteries of the tumor because of that high viscosity of the miriplatiniodized oil suspension. 21, 22 In the previous controlled studies, a warmed miriplatin-iodized oil suspension was not administered. [15] [16] [17] Seko et al. 21 reported the efficacy of TACE using miriplatin according to temperature conditions, for example, 44.3% of the patients treated with TACE with miriplatin in Japanese HCC patients E103 Hepatology Research 2018; 48: E98-E106 room temperature miriplatin, and 71.1% of the patients who received warmed miriplatin experienced CR or PR. If they had been treated with warmed miriplatin-iodized oil suspension in their TACE, the effects might have been better. Ikeda et al. 22 suggested that TACE with warmed miriplatin is a valuable medical technique in the treatment of multiple HCCs.
In the present study, although TTP was significantly different between the two groups, there was no significant difference in the response rate (miriplatin group, 79.8%; epirubicin group, 77.8%) (P = 0.862). This reason is due to an excessively slow release of active platinum from the tumor site where active platinum-iodized oil suspension is accumulated. 17, 23 In a previous study on rat hepatic tumors, only 6% of the total platinum was reported to be released into the surrounding parenchyma at 28 days after intra-arterial chemoinfusion of platinum-iodized oil suspension in the tumors. 17, 23 Moreover, the maximum plasma concentration time ranged from 18 to 37 days for the miriplatin study. 11, 17 Hino et al. 24 reported intra-arterial chemoinfusion of epirubicin-iodized oil suspension in rats, and showed that the maximum concentration of epirubicin in the liver was at 1 h. Therefore, although there was no significant difference in the response rate, the TTP in the miriplatin group was significantly longer than that in the epirubicin group, because sufficient plasma concentration of total platinum to combat tumor progression was retained in the target tumor for a prolonged period.
There are several limitations in this study. First, variations in patient background reduced the efficacy and safety by its being limited to Japanese patients. Second, survival was not reported in this study because more than 50% of the patients survived to the end of the analysis. Moreover, this study was a phase II trial that evaluated the local control efficacy of TACE with miriplatin or epirubicin. Third, the TACE procedures were not blinded, that is, this was an open-label trial; therefore, the physicians knew which anticancer agent, miriplatin or epirubicin, they were giving to each patient. Indeed, although there was no significant difference of ration of the TACE methods between the two groups, the results of the univariate analysis revealed a significant difference in the TACE methods (segmental or ultraselective/subsegmental). This nonblinded process might have affected the results. Finally, we could not prepare iodized oil doses for both groups.
The iodized oil dose of the miriplatin group (1.5 mL) was less than that of the epirubicin group (3.2 mL), but the dose was not a factor affecting tumor progression by multivariate analysis.
In conclusion, we showed that miriplatin was significantly more effective than epirubicin in TACE by this prospective, randomized, controlled study. Overall incidences of adverse events and adverse drug reactions did not differ significantly between the two groups. In future studies, further investigation for survival is warranted to evaluate the long-term therapeutic efficacy of miriplatin.
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